Tarsus Pharmaceuticals, INC Form 4 insider transactions

Tarsus Pharmaceuticals CEO Bobak R. Azamian sold 6,000 shares of common stock for approximately $497,000 through a pre-arranged 10b5-1 trading plan.

Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, reported gifting 475 shares of common stock to his daughter.

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold 7,397 shares of common stock for $80.1 per share under a pre-arranged 10b5-1 trading plan.

Tarsus Pharmaceuticals Director William J. Link, PhD, reported the sale of 22,946 shares of common stock totaling approximately $1.86 million on December 15, 2025.

Tarsus Pharmaceuticals' Chief Medical Officer, Elizabeth Yeu Lin, reported the vesting and settlement of restricted stock units and a subsequent 'sell to cover' transaction for tax obligations.

Tarsus Pharmaceuticals CEO Bobak R. Azamian transferred 51,885 shares of common stock to his living trust for no consideration, maintaining beneficial control.

Tarsus Pharmaceuticals CEO Bobak Azamian sold 6,000 shares of common stock for $55.37 per share under a pre-arranged 10b5-1 trading plan.

Tarsus Pharmaceuticals Director William J. Link gifted 2,000 shares of common stock, as reported in a recent SEC Form 4 filing.

Tarsus Pharmaceuticals director Scott W. Morrison settled vested Restricted Stock Units and adjusted his common stock holdings, resulting in an indirect beneficial ownership of 6,016 shares.

Tarsus Pharmaceuticals Director William J. Link, PhD, sold 27,116 shares of common stock for approximately $1.5 million in a pre-planned transaction.

Tarsus Pharmaceuticals CEO Bobak Azamian sold 6,000 shares of common stock for $50 per share under a pre-arranged 10b5-1 trading plan.

Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc., acquired common stock through RSU settlement and subsequently sold a portion to cover tax withholding obligations.

Tarsus Pharmaceuticals, Inc.'s Chief Medical Officer, Elizabeth Yeu Lin, reported the acquisition of common stock through RSU settlement and a subsequent non-discretionary sale to cover tax obligations.

Tarsus Pharmaceuticals, Inc. Director Andrew D. Goldberg reported the acquisition of common stock from RSU settlement, new stock options, and new restricted stock units related to his service.

Tarsus Pharmaceuticals, Inc. Director Bhaskar Chaudhuri reported the acquisition of common stock from vested Restricted Stock Units and new grants of stock options and Restricted Stock Units as part of his compensation.

Tarsus Pharmaceuticals, Inc. director Katherine Goodrich was granted annual equity awards comprising stock options and restricted stock units as part of her non-employee director compensation.

Tarsus Pharmaceuticals Director Wendy Yarno reported the acquisition of 3,350 common shares from RSU settlement, alongside new grants of 4,540 stock options and 2,954 Restricted Stock Units, reflecting her ongoing compensation as a non-employee director.

Scott W. Morrison, a Director at Tarsus Pharmaceuticals, Inc., has reported the acquisition of common stock through RSU settlement and new grants of stock options and Restricted Stock Units as part of his compensation.

Tarsus Pharmaceuticals, Inc. Director Dr. William J. Link filed a Form 4 detailing the settlement of vested Restricted Stock Units and the grant of new stock options and RSUs, reflecting standard equity compensation.

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, Inc., sold 17,500 shares of common stock for approximately $43.76 per share as part of a pre-scheduled Rule 10b5-1 trading plan.

Bobak Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, sold 6,000 shares of common stock at $50 per share on March 24, 2025, according to a Form 4 filing.

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Seshadri Neervannan, COO of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, sold shares of common stock between March 18 and March 20, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Tarsus Pharmaceuticals' CEO, Bobak R. Azamian, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reports the acquisition of common stock through the exercise of restricted stock units.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units.